Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q3 FY20 results · Oct–Dec 2019
Natco Pharma reported revenue from operations of ₹482.20 crore (down 13.4% from Q3 FY19) and net profit of ₹104.40 crore (down 34.5% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 482.20 | 556.70 | −13.4% | 485.70 | −0.7% |
| Other income | 30.80 | 23.30 | +32.2% | 33.20 | −7.2% |
| Total income | 513.00 | 580.00 | −11.6% | 518.90 | −1.1% |
| Profit before tax | 128.80 | 204.70 | −37.1% | 139.40 | −7.6% |
| Net profit for the period | 104.40 | 159.30 | −34.5% | 117.70 | −11.3% |
| Attributable to shareholders of the company | 104.50 | 159.50 | −34.5% | 119.00 | −12.2% |
| EPS, basic (₹) | 5.75 | 8.65 | −33.5% | 6.55 | −12.2% |
| Net margin (%) | 21.7 | 28.6 | 24.2 |
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 447.70 | 531.90 | −15.8% | 457.70 | −2.2% |
| Other income | 30.90 | 23.70 | +30.4% | 33.90 | −8.8% |
| Total income | 478.60 | 555.60 | −13.9% | 491.60 | −2.6% |
| Profit before tax | 127.30 | 206.40 | −38.3% | 143.60 | −11.4% |
| Net profit for the period | 103.60 | 162.00 | −36.0% | 122.20 | −15.2% |
| EPS, basic (₹) | 5.70 | 8.78 | −35.1% | 6.72 | −15.2% |
| Net margin (%) | 23.1 | 30.5 | 26.7 |
Consolidated
- Filed with BSE
- 12 Feb 2020, 17:36 IST
- Board meeting
- 12 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Feb 2020, 17:36 IST
- Board meeting
- 12 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE